Pemvidutide (ALT-801)

Mechanism of action: GLP-1 agonism; Glucagon agonism; Appetite suppression; Increased energy expenditure; Reduced hepatic fat

Proposed indications: Obesity; MASH; Fatty liver; Metabolic syndrome

Reported dosing range*: 1.2 or 1.8 mg once weekly, subcutaneous

A Phase 2b trial in metabolic dysfunction-associated steatohepatitis (MASH) evaluated once-weekly subcutaneous doses of 1.2 mg or 1.8 mg, administered without dose titration (Noureddin M et al. (2025). Safety and Efficacy of Weekly Pemvidutide Versus Placebo for Metabolic Dysfunction-Associated Steatohepatitis (IMPACT): 24-Week Results From a Multicentre, Randomised, Double-Blind, Phase 2b Study. The Lancet). The separate obesity-focused MOMENTUM trial (referenced below) may have used different doses -- not independently verified here.

*General range reported in available research or other sources -- not an individualized recommendation. Actual use should be supervised by a qualified provider.

Typical clinical dosing schedule: Investigational weekly dose-escalation regimens have been used in clinical studies.

Administration: Subcutaneous injection — Weekly

Compare with: Retatrutide (LY3437943)Survodutide (BI 456906)Cotadutide (MEDI0382)Tirzepatide

Evidence rating: ⭐⭐⭐☆☆ — Early trials show promising weight reduction and liver fat improvement.

Landmark trials: Altimmune Phase 2 MOMENTUM Trial (2024)

Common side effects: Nausea, Vomiting, Diarrhea

Serious risks: Long-term cardiovascular and hepatic safety remain under investigation.

Monitoring: Weight, Liver enzymes, Metabolic parameters

Legal status: Investigational. Not FDA-approved and not available by prescription — currently accessible only through enrollment in a clinical trial.

Regulatory status: Phase 2 • Not FDA Approved

Contraindications: Not established.

Altimmune Phase 2 MOMENTUM Trial (2024). Altimmune MASH clinical development program publications.